Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.73 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953313 | 0.98 | MET (0.74) | METCDKL5KCNH2 | |
| SCHEMBL1953334 | 0.97 | MET (0.76) | METCDKL5KCNH2 | |
| SCHEMBL1954142 | 0.93 | MET (0.71) | METCDKL5KCNH2 | |
| SCHEMBL1953861 | 0.91 | MET (0.75) | METCDKL5KCNH2 | |
| SCHEMBL3829046 | 0.90 | MET (0.66) | METCDKL5KCNH2 | |
| SCHEMBL20406899 | 0.89 | MET (0.79) | METCDKL5KCNH2 | |
| SCHEMBL13639759 | 0.88 | MET (0.63) | METCDKL5KCNH2 | |
| SCHEMBL22516149 | 0.88 | MET (0.77) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1426819 | 0.85 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL29429714 | 0.85 | MET (1.00) | METCDKL5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885KCNH2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.